Companies: 10,795·Total market cap: $144.5T
Chinook Therapeutics, Inc.

Chinook Therapeutics, Inc.

KDNYNASDAQHealthcare
$40.39
+$0.09(+0.22%)
Market Cap$2.7B
P/E Ratio—
52W High$40.51
52W Low$18.34
ForecastMarket CapPE Ratio

Chinook Therapeutics, Inc.（KDNY）股价预测与分析师目标价

华尔街共识、12 个月目标价、模型推演与 EPS/营收预期 — 来自分析师数据与历史行情。

kdny · 股价预测 · 11 位分析师（近3月）· FMP · 更新于 2024年3月26日

分析师评级与共识

基于过去 3 个月内 11 位华尔街分析师

SellBuy

Hold

11 位分析师

共识

评级分布

Strong Buy
0
Buy
2
Hold
9
Sell
0
Strong Sell
0
合计: 11 · 买入占比: 18.2%

12 个月目标价

High

$30.00

Consensus

$30.00

-25.7% upside

Low

$30.00

Median: $30 · Last Close: $40.39

Chinook Therapeutics, Inc.（KDNY）的分析师共识为 Hold，基于过去 3 个月内 11 位华尔街分析师的评级。KDNY 的 12 个月平均目标价为 $30.00，相对当前价 $40.39 代表 -25.7% 的潜在上行空间。

12 个月目标价预测

历史收盘价 + 分析师 12 个月目标价预测区间

分析师目标价覆盖不足，无法为该股票生成预测图表。

短期股价预测

⚠️ 短期模型暂不可用——近期成交量过低，信号不可靠。

长期股价预测

⚠️ 长期模型暂不可用——成交量过低，信号不可靠。

基于技术分析的股价预测

14 项技术面信号（SMA×6 + EMA×6 + RSI + MACD）· EEAT 方法论透明

Market Sentiment

NEUTRAL

Based on 14 technical indicators

43%50%7%
6Buy
7Neutral
1Sell
RSI (14)89.5Overbought
MACDBULLISH

Refreshes daily from EOD close

Moving Averages · KDNY · Jun 8, 2026

Simple Moving Average (SMA)
MA 5$40.39NEUTRAL
MA 10$40.37BUY
MA 20$39.97BUY
MA 50$0.00NEUTRAL
MA 100$0.00NEUTRAL
MA 200$0.00NEUTRAL
Current $KDNY · Price above MA = BUY signal
Exponential Moving Average (EMA)
EMA 5$40.38BUY
EMA 10$40.29BUY
EMA 20$40.01BUY
EMA 50$0.00NEUTRAL
EMA 100$0.00NEUTRAL
EMA 200$0.00NEUTRAL
Current $KDNY · Price above MA = BUY signal
How we calculate: Technical sentiment is derived from 14 indicators — SMA(5,10,20,50,100,200), EMA(5,10,20,50,100,200), RSI(14), and MACD(12,26,9) — calculated from historical EOD price data. BUY = current price above MA; SELL = below. 14 TA signals + historical EOD price data · Updated daily. Independent of analyst consensus data. Not investment advice.

最新分析师评级与调整

Filter:
Wedbush2023-08-08
Downgrade ↓
Outperform→Neutral
Wedbush2023-08-07
Downgrade ↓
Outperform→Neutral
Wells Fargo2023-08-01
Downgrade ↓
Overweight→Equal Weight
Wells Fargo2023-07-31
Downgrade ↓
Overweight→Equal Weight
HC Wainwright & Co.2023-06-21
Maintains
Neutral→Neutral
HC Wainwright & Co.2023-06-20
Maintains
Neutral→Neutral
Evercore ISI Group2023-06-14
Downgrade ↓
Outperform→In Line
SVB Leerink2023-06-13
Downgrade ↓
Outperform→Perform
Stifel2023-06-13
Downgrade ↓
Buy→Hold
Evercore ISI Group2023-06-13
Downgrade ↓
Outperform→In Line

Wall Street analysts have recently issued updated ratings on Chinook Therapeutics, Inc. (KDNY) stock. Of the recent 46 rating actions, 1 were upgrades and 18 were downgrades. 11 analysts currently cover KDNY.

分析师推荐趋势

Buy ratings5 → 0↓ 5
Hold ratings0 → 3↑ +3
Sell ratings0 → 0

KDNY analyst recommendation trends show decreasing buy-side sentiment over the past 6 months. Buy rating actions changed from 5 to 0 per month.

财务预测：EPS 与营收一致预期

Revenue This Year

—

Revenue Next Year

—

EPS This Year

—

EPS Next Year

—

EPS ForecastReported vs Estimated

Reported EPSHistorical estimateAnalyst forecast (future)

Analysts forecast KDNY EPS of $— for the current fiscal year, based on estimates from 0 analysts. The KDNY revenue forecast is — for the current year. These are analyst consensus estimates via FMP / S&P Global.

关于预测与目标价

KDNY 股价预测由两类独立数据源支撑：来自 11 位华尔街分析师（S&P Global / FMP）的共识评级，以及基于历史日终价计算的技术分析。KDNY 的共识目标价为 $30.00（-25.7% 上行空间），分析师共识为 Hold。

Chinook Therapeutics, Inc. 在 NASDAQ 上市，代码 KDNY。KDNY 在 2027 年的整体展望偏中性/分化，在覆盖分析师中约 18% 对应 Hold 共识。

常见问题答案综合分析师目标价、一致预期及页面展示的模型结果。

相关页面

盈利营收市盈率财务报表市值内幕交易股息价格历史

常见问题

KDNY 预测 · 8 个问题

根据 11 位华尔街分析师，KDNY 的 12 个月平均目标价为 $30.00，最高 $30.00、最低 $30.00。若有图表，中位目标价可在上方查看。相对当前价 $40.39，隐含约 -25.7% 的上行空间。

KDNY 目标价KDNY 分析师目标价KDNY 12个月目标价目标价 KDNY

· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)

⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.